Trials / Not Yet Recruiting
Not Yet RecruitingNCT07518186
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 700 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-79635322 | JNJ-79635322 will be administered as SC injection. |
| DRUG | Teclistamab | Teclistamab will be administered as SC injection. |
Timeline
- Start date
- 2026-06-08
- Primary completion
- 2029-04-29
- Completion
- 2032-12-08
- First posted
- 2026-04-08
- Last updated
- 2026-04-13
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07518186. Inclusion in this directory is not an endorsement.